Guaifenesin

Guaifenesin
Clinical data
Pronunciation/ɡwaɪˈfɛnɪsɪn/
gwy-FEH-nih-sin
Trade namesMucinex, others
Other namesGlyceryl guaiacolate
AHFS/Drugs.comMonograph
MedlinePlusa682494
License data
Routes of
administration
By mouth
Drug classExpectorant
ATC code
Legal status
Legal status
Pharmacokinetic data
MetabolismKidney
Elimination half-life1–5 hours
Identifiers
  • (RS)-3-(2-methoxyphenoxy)propane-1,2-diol
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.002.021
Chemical and physical data
FormulaC10H14O4
Molar mass198.218 g·mol−1
3D model (JSmol)
ChiralityRacemic mixture
  • O(c1ccccc1OC)CC(O)CO
  • InChI=1S/C10H14O4/c1-13-9-4-2-3-5-10(9)14-7-8(12)6-11/h2-5,8,11-12H,6-7H2,1H3 checkY
  • Key:HSRJKNPTNIJEKV-UHFFFAOYSA-N checkY
  (verify)

Guaifenesin, also known as glyceryl guaiacolate, which is sold under many brand names including Mucinex, is an expectorant medication taken by mouth and marketed as an aid to eliminate sputum from the respiratory tract. Chemically, it is an ether of guaiacol and glycerine. It may be used in combination with other medications. A 2014 study found that guaifenesin does not affect sputum volume in upper respiratory infections (the upper respiratory system includes most breathing parts above the lungs). In 2023, guaifenesin was alleged to work by increasing the liquid content in airway secretions.

Side effects may include dizziness, sleepiness, skin rash, and nausea. While it has not been properly studied in pregnancy, it appears to be safe.

Guaifenesin has been used medically since at least 1933. It is available as a generic medication and over-the-counter (OTC). In 2023, it was the 291st most commonly prescribed medication in the United States, with more than 500,000 prescriptions. In 2023, the combination dextromethorphan/guaifenesin was the 315th most commonly prescribed medication in the United States, with more than 200,000 prescriptions.